Covered recipient · General Payments record
CALISTA MAE VINYARD
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2023–2024
$482.75
- Reported across 23 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $389.90 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Indivior Inc. | $174.08 | 7 |
| ABBVIE INC. | $76.65 | 4 |
| Braeburn Inc. | $71.65 | 3 |
| GlaxoSmithKline, LLC. | $25.93 | 1 |
| Exact Sciences Corporation | $21.41 | 1 |
| ITI, Inc. | $20.18 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $13.17 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106286930 | CMS |
| ABBVIE INC. | $17.04 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106286932 | CMS |
| ABBVIE INC. | $22.31 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106286934 | CMS |
| ABBVIE INC. | $24.13 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106286936 | CMS |
| Braeburn Inc. | $16.38 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125599629 | CMS |
| Braeburn Inc. | $23.84 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125599631 | CMS |
| Braeburn Inc. | $31.43 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125599633 | CMS |
| Exact Sciences Corporation | $21.41 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114525734 | CMS |
| GlaxoSmithKline, LLC. | $25.93 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116357684 | CMS |
| Indivior Inc. | $19.07 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144540077 | CMS |
| Indivior Inc. | $23.30 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144540079 | CMS |
| Indivior Inc. | $30.81 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144540081 | CMS |
| Indivior Inc. | $25.88 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144540083 | CMS |
| Indivior Inc. | $31.03 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144540085 | CMS |
| Indivior Inc. | $24.08 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144540087 | CMS |
| Indivior Inc. | $19.91 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144540089 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.18 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143339529 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.